Shandong Boan Biotechnology Co. Ltd., a joint stock company based in the People's Republic of China, has announced the placement of 38,400,000 new shares under a general mandate. This represents approximately 7.17% of the company's total shares in issue. The company has entered into an agreement with a Placing Agent to facilitate the sale of these new shares on a best effort basis. The initiative is part of the company's strategy to raise capital and strengthen its financial position. The shares are listed on the Main Board of the Stock Exchange of Hong Kong, under the stock code 6955.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.